Adlai Nortye (ANL) Competitors $1.58 +0.03 (+1.61%) Closing price 08/8/2025 03:58 PM EasternExtended Trading$1.58 0.00 (0.00%) As of 08/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. CGC, CRGX, FDMT, NLTX, DMAC, EPRX, GALT, GNFT, IPHA, and LYELShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Canopy Growth (CGC), CARGO Therapeutics (CRGX), 4D Molecular Therapeutics (FDMT), Neoleukin Therapeutics (NLTX), DiaMedica Therapeutics (DMAC), Eupraxia Pharmaceuticals (EPRX), Galectin Therapeutics (GALT), GENFIT (GNFT), Innate Pharma (IPHA), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Its Competitors Canopy Growth CARGO Therapeutics 4D Molecular Therapeutics Neoleukin Therapeutics DiaMedica Therapeutics Eupraxia Pharmaceuticals Galectin Therapeutics GENFIT Innate Pharma Lyell Immunopharma Adlai Nortye (NASDAQ:ANL) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability. Do institutionals and insiders believe in ANL or CGC? 35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 1.3% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend ANL or CGC? Adlai Nortye currently has a consensus target price of $9.00, indicating a potential upside of 471.43%. Given Adlai Nortye's stronger consensus rating and higher possible upside, analysts plainly believe Adlai Nortye is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Canopy Growth 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk & volatility, ANL or CGC? Adlai Nortye has a beta of -0.95, indicating that its share price is 195% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Does the media refer more to ANL or CGC? In the previous week, Canopy Growth had 6 more articles in the media than Adlai Nortye. MarketBeat recorded 6 mentions for Canopy Growth and 0 mentions for Adlai Nortye. Canopy Growth's average media sentiment score of 0.36 beat Adlai Nortye's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media. Company Overall Sentiment Adlai Nortye Neutral Canopy Growth Neutral Which has stronger earnings and valuation, ANL or CGC? Adlai Nortye has higher earnings, but lower revenue than Canopy Growth. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M11.62-$51.87MN/AN/ACanopy Growth$225.65M1.14-$429.86M-$4.04-0.31 Is ANL or CGC more profitable? Adlai Nortye has a net margin of 0.00% compared to Canopy Growth's net margin of -195.76%. Adlai Nortye's return on equity of 0.00% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Canopy Growth -195.76%-88.54%-40.78% SummaryAdlai Nortye beats Canopy Growth on 8 of the 13 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.56M$2.99B$5.52B$9.72BDividend YieldN/A2.42%4.60%4.12%P/E RatioN/A17.2130.0124.75Price / Sales11.62310.81450.0597.82Price / CashN/A41.7736.7758.47Price / Book2.287.318.185.59Net Income-$51.87M-$54.43M$3.26B$265.99M7 Day Performance8.25%0.01%6.13%5.06%1 Month Performance1.61%0.63%0.07%0.61%1 Year Performance-52.08%8.41%36.31%22.82% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye1.7263 of 5 stars$1.58+1.6%$9.00+471.4%-52.1%$57.56M$5M0.00127CGCCanopy Growth0.383 of 5 stars$1.03-6.0%N/A-80.4%$210.28M$269.00M-0.253,150News CoverageEarnings ReportGap UpCRGXCARGO Therapeutics2.4673 of 5 stars$4.50-0.1%$15.40+242.6%-67.9%$207.26MN/A-0.97116Positive NewsUpcoming EarningsFDMT4D Molecular Therapeutics2.5026 of 5 stars$4.41-4.9%$29.56+570.0%-62.0%$204.29M$23K-1.39120NLTXNeoleukin TherapeuticsN/A$21.68-4.6%N/A-40.4%$203.75MN/A-6.9790Gap UpDMACDiaMedica Therapeutics1.734 of 5 stars$4.69-7.4%$10.75+129.5%+31.5%$202.18MN/A-7.3720EPRXEupraxia Pharmaceuticals2.7466 of 5 stars$5.61-1.0%$11.00+96.0%+96.3%$201.76MN/A-7.3829GALTGalectin Therapeutics2.4128 of 5 stars$3.18+3.8%$6.00+89.0%+103.4%$200.95MN/A-4.419Upcoming EarningsGNFTGENFIT1.578 of 5 stars$4.01-3.6%$13.00+224.2%-4.6%$200.50M$76.77M0.00120Gap UpIPHAInnate Pharma2.326 of 5 stars$2.14-2.7%$11.00+414.0%-3.5%$197.27M$12.62M0.00220News CoverageLYELLyell Immunopharma3.315 of 5 stars$13.25-3.5%$15.00+13.2%-64.1%$196.83M$60K-0.53270 Related Companies and Tools Related Companies Canopy Growth Alternatives CARGO Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Neoleukin Therapeutics Alternatives DiaMedica Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Galectin Therapeutics Alternatives GENFIT Alternatives Innate Pharma Alternatives Lyell Immunopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANL Stock Alerts